| Cat. No. |
Product Name |
Information |
| PC-20901 |
YLIU-5-162-1
JAK2 inhibitor
|
YLIU-4-105-1 is a novel type II JAK2 inhibitor, binds to JAK2 kinase domain (JH1), show potential for overcoming acquired resistance to ruxolitinib. |
| PC-20543 |
ABT-317
JAK1 inhibitor
|
ABT-317 (ABT317) is a potent, selective JAK1 inhibitor, inhibits IL-6-stimulated pSTAT3 (TF-1 cells, IC50=16 nM) and IL-2-stimulated pSTAT5 (T-blasts, IC50=30 nM). |
| PC-20143 |
CEE321
pan JAK inhibitor
|
CEE321 (CEE-321) is a potent, selective pan-JAK inhibitor with IC50 of 50, 48, 59 and 48 nM for JAK1, JAK2, JAK3 and TYK2, respectively. |
| PC-20060 |
Nimucitinib
JAK inhibitor
|
Nimucitinib is a potent, selective Janus kinase (JAK) inhibitor. |
| PC-49397 |
Ifidancitinib
JAK inhibitor
|
Ifidancitinib (ATI-502, ATI-50002, R507) is a potent and selective next-generation JAK1/3 inhibitor, potently inhibits γc cytokine signaling. |
| PC-49377 |
JAK-IN-21
JAK inhibitor
|
JAK-IN-21 is a selective and potent JAK inhibitor with IC50 of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively. |
| PC-49307 |
AZD0449
JAK1 inhibitor
|
AZD0449 (AZD-0449) is a potent and highly selective JAK1 inhibitor with IC50 of 2.4 nM, displays >50-fold selectivity over TYK2 and JAK2, and no inhibition against JAK3. |
| PC-49274 |
Z583
JAK3 inhibitor
|
Z583 is a potent, highly selective JAK3 inhibitor with IC50 of 0.1 nM, 4500-fold selectivity over other JAK subtypes. |
| PC-38399 |
Ilunocitinib
JAK inhibitor
|
Ilunocitinib is a potent, small molecule JAK inhibitor. |
| PC-38381 |
Nezulcitinib
pan JAK inhibitor
|
Nezulcitinib (TD-0903) is a inhaled lung-selective pan-JAK inhibitor, targets all JAK isoforms (JAK1, JAK2, JAK3, TYK2), Nezulcitinib is under development for treatment of acute lung injury associated with COVID-19. |
| PC-73438 |
Povorcitinib
JAK1 inhibitor
|
Povorcitinib is a potent, selective JAK1 inhibitor with anti-inflammatory activity. |
| PC-73423 |
Ivarmacitinib
JAK1 inhibitor
|
Ivarmacitinib (SHR0302) is a potent highly selective, Janus kinase 1 (JAK1) inhibitor with IC50 of 0.1 nM, 9-fold selectivity over JAK2 and >70-fold over JAK3 and TYK2. |
